Want to see IN:LYKALABS full AI Analyst Report?
LYKALABS Stock Chart & Stats
₹94.40
-₹1.55(-0.97%)
At close: 4:00 PM EST
₹94.40
-₹1.55(-0.97%)
Day’s Range― - ―
52-Week Range₹44.49 - ₹104.80
Previous CloseN/A
Volume78.41K
Average Volume (3M)3.39K
Market Cap
₹2.75B
Enterprise Value₹2.06K
Total Cash (Recent Filing)₹18.93M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Nov 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.50
Shares Outstanding36,152,710
10 Day Avg. Volume2,785
30 Day Avg. Volume3,390
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.74
Price to Sales (P/S)1.25
P/FCF Ratio-21.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt Reduction And Positive EquitySubstantial deleveraging has reduced financial pressure and improved the balance-sheet foundation. Positive equity provides greater resilience than in earlier periods, although the company’s history of high leverage means financial flexibility still requires monitoring.
Positive Operating Cash FlowPositive operating cash generation indicates that the core business still converts activity into cash even during a loss-making year. This provides some internal funding capacity, though the modest level is insufficient to offset capital needs fully.
Established Pharmaceutical Manufacturing BaseParticipation across pharmaceutical manufacturing, development and product sales gives Lyka Labs an established operating base in healthcare. Demand for medicines is structurally recurring, supporting business relevance beyond short-term market conditions.
Bears Say
Revenue ContractionThe latest revenue decline signals weaker commercial performance and limits operating leverage. If the contraction persists, scale benefits and the company’s ability to absorb fixed manufacturing and administrative costs could remain constrained.
Return To Operating And Net LossesThe sharp swing from profit to operating and net losses demonstrates unstable earnings quality and cost control. Repeated profitability reversals weaken retained capital, reduce funding capacity and make future investment in products more difficult.
Persistently Negative Free Cash FlowSustained negative free cash flow indicates that operating cash does not cover ongoing investment and other cash requirements. This limits self-funding capacity and may increase reliance on financing or asset monetisation over time.
Lyka Labs Limited News
LYKALABS FAQ
What was Lyka Labs Limited’s price range in the past 12 months?
Lyka Labs Limited lowest stock price was ₹44.49 and its highest was ₹104.80 in the past 12 months.
What is Lyka Labs Limited’s market cap?
Lyka Labs Limited’s market cap is ₹2.75B.
When is Lyka Labs Limited’s upcoming earnings report date?
Lyka Labs Limited’s upcoming earnings report date is Nov 14, 2026 which is in 71 days.
How were Lyka Labs Limited’s earnings last quarter?
Lyka Labs Limited released its earnings results on Aug 10, 2026. The company reported ₹0.571 earnings per share for the quarter.
Is Lyka Labs Limited overvalued?
According to Wall Street analysts Lyka Labs Limited’s price is currently Overvalued.
Does Lyka Labs Limited pay dividends?
Lyka Labs Limited does not currently pay dividends.
What is Lyka Labs Limited’s EPS estimate?
Lyka Labs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lyka Labs Limited have?
Lyka Labs Limited has 36,152,710 shares outstanding.
What happened to Lyka Labs Limited’s price movement after its last earnings report?
Lyka Labs Limited reported an EPS of ₹0.571 in its last earnings report. Following the earnings report the stock price went up 1.996%.
Which hedge fund is a major shareholder of Lyka Labs Limited?
Currently, no hedge funds are holding shares in IN:LYKALABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lyka Labs Limited
Established in 1976 and headquartered in Mumbai, India, Lyka Labs Limited is a pharmaceutical firm specializing in the development, manufacturing, and marketing of a wide array of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company's extensive product portfolio addresses numerous therapeutic areas, including intensive care, gastroenterology, anti-infectives, anti-fungals, surgery, urology, wound care, anesthesia, and various dermatological and cosmeceutical applications like topical steroids, anti-acne, anti-aging, and hair care. These products are available in diverse forms, such as injections, creams, ointments, gels, and lotions. Beyond its own offerings, Lyka Labs also provides contract manufacturing services to other major pharmaceutical companies and offers comprehensive medical and technical support. This support includes manufacturing expertise, facility assistance, and crucial technical data such as molecule stability testing, impurity profiling, and bioequivalence (BA/BE) clinical study data. The company's market reach extends globally, with exports to various countries including Bangladesh, Cambodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam.
Technical Analysis
Dishman Carbogen Amcis Ltd.
―
Panacea Biotec Limited
―
SMS Lifesciences India Ltd.
―
Supriya Lifescience Limited
―
Zota Health Care Ltd.
―